

November 19, 2021

Kris Vaddi, Ph.D.
Chief Executive Officer
Prelude Therapeutics Inc
200 Powder Mill Road
Wilmington, Delaware 19803

Therapeutics Inc
Statement on Form S-3
2021

Re: Prelude
Registration
Filed November 12,
File No. 333-261019

Dear Kris Vaddi:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael Davis at 202-551-4385 or Joe McCann at 202-551-6262 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Robert Freedman